Lehe Yang

1.2k total citations
42 papers, 878 citations indexed

About

Lehe Yang is a scholar working on Oncology, Molecular Biology and Toxicology. According to data from OpenAlex, Lehe Yang has authored 42 papers receiving a total of 878 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 21 papers in Molecular Biology and 10 papers in Toxicology. Recurrent topics in Lehe Yang's work include Cytokine Signaling Pathways and Interactions (19 papers), Bioactive Compounds and Antitumor Agents (10 papers) and Cancer Mechanisms and Therapy (6 papers). Lehe Yang is often cited by papers focused on Cytokine Signaling Pathways and Interactions (19 papers), Bioactive Compounds and Antitumor Agents (10 papers) and Cancer Mechanisms and Therapy (6 papers). Lehe Yang collaborates with scholars based in China, United States and India. Lehe Yang's co-authors include Xiaoying Huang, Chengguang Zhao, Lingyuan Xu, Liangxing Wang, Youqun Xiang, Chengguang Zhao, Xuanxuan Dai, Guang Liang, Haiyang Zhao and Jifa Li and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Lehe Yang

40 papers receiving 872 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lehe Yang China 18 396 275 134 124 111 42 878
Tianqi Ming China 11 595 1.5× 186 0.7× 201 1.5× 61 0.5× 118 1.1× 16 1.1k
Cynthia Cunningham United States 15 369 0.9× 189 0.7× 129 1.0× 84 0.7× 88 0.8× 27 920
Huameng Li United States 15 417 1.1× 335 1.2× 87 0.6× 57 0.5× 74 0.7× 19 946
Nipin Sp South Korea 19 587 1.5× 202 0.7× 186 1.4× 43 0.3× 89 0.8× 41 1.2k
Eric Schwartz United States 17 412 1.0× 336 1.2× 95 0.7× 153 1.2× 152 1.4× 30 1.1k
Jimin Zhao China 17 509 1.3× 213 0.8× 156 1.2× 48 0.4× 99 0.9× 70 897
Benson Chellakkan Selvanesan India 18 489 1.2× 209 0.8× 209 1.6× 69 0.6× 45 0.4× 27 987
Bano Shabnam India 9 485 1.2× 125 0.5× 173 1.3× 48 0.4× 45 0.4× 13 825
Jiajie Guo China 18 763 1.9× 115 0.4× 105 0.8× 78 0.6× 41 0.4× 51 1.4k
Xiao‐Wu Chen China 16 575 1.5× 205 0.7× 99 0.7× 68 0.5× 70 0.6× 32 1.1k

Countries citing papers authored by Lehe Yang

Since Specialization
Citations

This map shows the geographic impact of Lehe Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lehe Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lehe Yang more than expected).

Fields of papers citing papers by Lehe Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lehe Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lehe Yang. The network helps show where Lehe Yang may publish in the future.

Co-authorship network of co-authors of Lehe Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Lehe Yang. A scholar is included among the top collaborators of Lehe Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lehe Yang. Lehe Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xian, Xiao Lin, Yuxin Liu, et al.. (2025). Raddeanin A exerts potent efficacy against non-small cell lung cancer by inhibiting cyclin-dependent kinase 6. Translational Oncology. 56. 102382–102382. 1 indexed citations
2.
3.
Xu, Min, Mengjie Qiu, Yi Zhou, et al.. (2024). Solamargine improves the therapeutic efficacy of anti-PD-L1 in lung adenocarcinoma by inhibiting STAT1 activation. Phytomedicine. 128. 155538–155538. 4 indexed citations
4.
Cai, Xueding, et al.. (2024). Correlation between RNA N6-methyladenosine and ferroptosis in cancer: current status and prospects. Frontiers in Cell and Developmental Biology. 12. 1252064–1252064. 4 indexed citations
5.
Zhou, Feng, Yizhou Quan, Hongyan Qu, et al.. (2024). Demethylzeylasteral exerts potent efficacy against non-small-cell lung cancer via the P53 signaling pathway. Translational Oncology. 46. 101989–101989. 4 indexed citations
6.
Zhu, Yu, Meng Shi, Luyao Zhang, et al.. (2024). Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1/STAT3 signaling pathway. Chinese Journal of Natural Medicines. 22(4). 318–328. 4 indexed citations
7.
Liu, Conghui, Ying Bai, Lehe Yang, et al.. (2023). Acetyl-cinobufagin suppresses triple-negative breast cancer progression by inhibiting the STAT3 pathway. Aging. 15(16). 8258–8274. 11 indexed citations
8.
Zhou, Feng, Luyao Li, Yanmao Wang, et al.. (2023). Pharmacological targeting of MTHFD2 suppresses NSCLC via the regulation of ILK signaling pathway. Biomedicine & Pharmacotherapy. 161. 114412–114412. 8 indexed citations
9.
Zheng, Hailun, et al.. (2023). Cinobufagin exerts an antitumor effect in non-small-cell lung cancer by blocking STAT3 signaling. Journal of Cancer. 14(17). 3309–3320. 3 indexed citations
10.
Wang, Yanmao, Xian Wang, Haijian Cai, et al.. (2022). Acetylshikonin exerts anti-tumor effects on non-small cell lung cancer through dual inhibition of STAT3 and EGFR. Phytomedicine. 101. 154109–154109. 14 indexed citations
11.
Wang, Yanmao, Xian Wang, Luyao Zhang, et al.. (2022). Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer. Journal of Translational Medicine. 20(1). 525–525. 31 indexed citations
12.
Ye, Hua, Chengguang Zhao, Lehe Yang, et al.. (2020). Twelve out of 117 recovered COVID-19 patients retest positive in a single-center study of China. EClinicalMedicine. 26. 100492–100492. 7 indexed citations
13.
Zhao, Chunling, Wei Cao, Hongwei Zheng, et al.. (2019). Acid-responsive nanoparticles as a novel oxidative stress-inducing anticancer therapeutic agent for colon cancer. SHILAP Revista de lepidopterología. 1 indexed citations
14.
Yang, Lehe, et al.. (2019). Novel activators and small-molecule inhibitors of STAT3 in cancer. Cytokine & Growth Factor Reviews. 49. 10–22. 98 indexed citations
15.
Yang, Lehe, Jifa Li, Lingyuan Xu, et al.. (2019). <p>Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway</p>. Cancer Management and Research. Volume 11. 1167–1176. 45 indexed citations
16.
Yang, Lehe, Youqun Xiang, Lingyuan Xu, et al.. (2019). Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. Journal of Experimental & Clinical Cancer Research. 38(1). 31–31. 74 indexed citations
17.
Zheng, Hailun, Lehe Yang, Min Chen, et al.. (2018). Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling. Molecular Carcinogenesis. 58(4). 565–576. 53 indexed citations
18.
Yu, Fangyou, Jingye Pan, Baixing Ding, et al.. (2010). Prevalence of plasmid-mediated 16S rRNA methylase genes among Proteus mirabilis isolates from a Chinese hospital. African Journal of Microbiology Research. 4(24). 2790–2794. 1 indexed citations
19.
Yu, Fangyou, Qiang Chen, Jingye Pan, et al.. (2010). High prevalence of plasmid-mediated quinolone resistance determinant aac(6′)-Ib-cr amongst Salmonella enterica serotype Typhimurium isolates from hospitalised paediatric patients with diarrhoea in China. International Journal of Antimicrobial Agents. 37(2). 152–155. 21 indexed citations
20.
Yu, Fangyou, Dan Yao, Jingye Pan, et al.. (2010). High prevalence of plasmid-mediated 16S rRNA methylase gene rmtB among Escherichia coliclinical isolates from a Chinese teaching hospital. BMC Infectious Diseases. 10(1). 184–184. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tianqi Ming Breakdown of academic impact, for papers by Cynthia Cunningham Breakdown of academic impact, for papers by Huameng Li Breakdown of academic impact, for papers by Nipin Sp Breakdown of academic impact, for papers by Eric Schwartz Breakdown of academic impact, for papers by Jimin Zhao Breakdown of academic impact, for papers by Benson Chellakkan Selvanesan Breakdown of academic impact, for papers by Bano Shabnam Breakdown of academic impact, for papers by Jiajie Guo Breakdown of academic impact, for papers by Xiao‐Wu Chen
Rankless by CCL
2026